Latest Industry Insights

The pipeline to new drugs isn’t straightforward, but pharmas can pool their data resources to speed things up. The MELLODDY consortium hopes to make data sharing simple and secure. We talked to Hugo Ceulemans, MELLODDY Project Leader and Mathieu Galtier, Project Coordinator at Owkin to find out more.

Imagine if there was a better way to write, format, and review scientific manuscripts for publication. doDOC Document Collaboration Expert Leif Måsvær believes there is. Leif explains how this cloud-based platform is a game-changer that overcomes the major obstacles present during the authoring, writing, and reviewing process.

We recently spoke with Eric Hobbs, CEO at Berkeley Lights to learn more about "digital cell biology". Eric also describes how optofluidics can be used to gain fast, comprehensive measurements and insights across thousands of cells in parallel.

We recently spoke with Tyler Golato, Lead Scientist at Molecule, to learn more about the "innovation crisis", the factors directly impacting the types of therapeutics being brought to market, and how by uniting stakeholders it is possible to streamline the drug development pipeline.

In this interview, we spoke with Knut Wintergerst, PhD, General Manager of Biomolecular Systems and Solutions (BSS) and Diagnostics and Genomics Group (DGG) at Agilent to learn more about why DNA and RNA sample integrity is important to scientists and how it can be maintained and analyzed.

Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. We spoke with John Gebler, PhD, Director of Strategic Business Development at Waters Corporation to learn more about the BioAccord System and its applications.

Pupillometry is an ingenious way of assessing brain health by measuring data from patients’ eyes. New technology has helped standardize pupillometry, and these measurements are now helping treat patients with life-threatening brain injuries. We spoke to Kathleen Pierson, Vice President, Global Sales and Marketing, at pupillometry leader NeurOptics, to find out more.

Whilst some aspects of biochemistry research have become increasingly high-throughput, other, like analysis of chemical data, are too often laborious and slow. We talked to Andrew Anderson, Vice President of Innovation and Informatics Strategy at ACD/Labs about how the field is being changed by automation and how Katalyst hopes to speed up pharmaceutical development.

The Zika virus poses a significant global risk, and there is currently no vaccine or specific treatment available for those infected. Having access to sensitive and specific diagnostic assays is essential to disease management, and in enabling effective research and the development of therapeutics. We spoke to Nick Roesen, Founder and COO of The Native Antigen Company, to learn about the Zika virus immunoassays that have been developed to overcome cross-reactivity with Dengue.

Antibodies are an essential part of everyday neuroscience research. But recently, high-profile criticism has cast doubt on their reliability and reproducibility. We caught up with Bio-Techne’s Raymond Chan and Katherine Bradley to find out how providers are hoping to improve antibodies and make them fit for a more reproducible future in neuroscience.